Status:
COMPLETED
Immunogenicity of the BNT162b2 Covid-19 Vaccine in Elderly People Aged 85 and Older in Greece
Lead Sponsor:
G.Gennimatas General Hospital
Collaborating Sponsors:
Aristotle University Of Thessaloniki
Conditions:
Immunogenicity, Vaccine
Eligibility:
All Genders
85-100 years
Brief Summary
Real-world evidence confirming the effectiveness and safety of the new COVID-19 vaccines among the elderly is currently lacking. However, scarce (sparse) data derived from phase II/III trials attest t...
Detailed Description
Real world data regarding the effectiveness and safety of the new COVID-19 vaccines in older people are currently lacking. The sparse data from Phase II/II trials suggest a reduction in antibody respo...
Eligibility Criteria
Inclusion
- Age of 85 or older
- Without previously known SARS-CoV-2 infection, or
- With previous PCR-confirmed SARS-CoV-2 infection one to 4.5 months prior to vaccination
Exclusion
- Occurence of any other vaccination 4 weeks prior to enrollment
- Participation in any other clinical trial
Key Trial Info
Start Date :
February 13 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2021
Estimated Enrollment :
297 Patients enrolled
Trial Details
Trial ID
NCT04756817
Start Date
February 13 2021
End Date
September 30 2021
Last Update
August 5 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
G. Gennimatas General Hospital
Thessaloniki, Thessaloniki, Greece, 54635